Related Experiment Videos
Aminoglutethimide-induced hyperkalaemia
The British Journal of Clinical Practice
|July 1, 1989
Summary
Aminoglutethimide treatment for metastatic breast cancer can cause severe hyperkalemia, a rare complication. Regular monitoring or prophylactic mineralocorticoid replacement is crucial for patient safety during therapy.
Area of Science:
- Endocrinology
- Oncology
Background:
- Aminoglutethimide is used to inhibit adrenal hormone synthesis for metastatic breast carcinoma pain relief.
- Adrenal hormone synthesis inhibition can lead to potential endocrine complications.
Observation:
- A patient on long-term aminoglutethimide with cortisone supplements developed severe hyperkalemia.
- The patient also experienced adrenal failure due to glucocorticoid deficiency, requiring increased cortisone dosage.
Findings:
- This case represents the first reported instance of aminoglutethimide-induced hyperkalemia, highlighting its rarity.
- The complication suggests a need for careful management of mineralocorticoid and glucocorticoid replacement during therapy.
Implications:
- Constant biochemical monitoring is essential for patients receiving aminoglutethimide.
- Prophylactic mineralocorticoid replacement, such as fluorohydrocortisone, may be warranted.
- Regular review of glucocorticoid and mineralocorticoid status is vital to manage patient needs and counteract stress during treatment.